Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$15.31
At close: May 21 EDT
$15.25
-0.06-0.39%
Pre-Market: 7:49 PM EDT
Comments
Loading...
Arrowhead Pharma Analyst Ratings and Price Targets | NASDAQ:ARWR | Benzinga
Arrowhead Pharmaceuticals Inc has a consensus price target of $47 based on the ratings of 20 analysts. The high is $80 issued by HC Wainwright & Co. on May 20, 2025. The low is $17 issued by Citigroup on May 13, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citigroup, and Chardan Capital on May 20, 2025, May 13, 2025, and May 13, 2025, respectively. With an average price target of $52.33 between HC Wainwright & Co., Citigroup, and Chardan Capital, there's an implied 243.17% upside for Arrowhead Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citigroup
Chardan Capital
B. Riley Securities
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Arrowhead Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 424.59% | HC Wainwright & Co. | Patrick Trucchio46% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2025 | Buy Now | 11.48% | Citigroup | Shawn Egan51% | $21 → $17 | Maintains | Neutral | Get Alert |
| 05/13/2025 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 149.18% | B. Riley Securities | Mayank Mamtani71% | $51 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 424.59% | HC Wainwright & Co. | Patrick Trucchio46% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 175.41% | RBC Capital | Luca Issi42% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 02/11/2025 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | 424.59% | HC Wainwright & Co. | Patrick Trucchio46% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 424.59% | HC Wainwright & Co. | Patrick Trucchio46% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 424.59% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $80 | Maintains | Buy | Get Alert |
| 11/29/2024 | Buy Now | 57.38% | Bernstein | William Pickering38% | $27 → $24 | Maintains | Market Perform | Get Alert |
| 11/27/2024 | Buy Now | 195.08% | Piper Sandler | Edward Tenthoff50% | $62 → $45 | Maintains | Overweight | Get Alert |
| 11/27/2024 | Buy Now | 70.49% | Citigroup | Shawn Egan51% | $27 → $26 | Maintains | Neutral | Get Alert |
| 11/27/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/08/2024 | Buy Now | 306.56% | Piper Sandler | Edward Tenthoff50% | $62 → $62 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2024 | Buy Now | 175.41% | RBC Capital | Luca Issi42% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer51% | — | Reiterates | → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 260.66% | B. Riley Securities | Mayank Mamtani71% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/17/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 07/05/2024 | Buy Now | 293.44% | HC Wainwright & Co. | Patrick Trucchio46% | $90 → $60 | Maintains | Buy | Get Alert |
| 06/26/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | — | Reiterates | → Overweight | Get Alert |
| 06/11/2024 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 103.28% | Goldman Sachs | Andrea Tan37% | → $31 | Initiates | → Neutral | Get Alert |
| 06/03/2024 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 77.05% | Morgan Stanley | Michael Ulz63% | $36 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | $60 → $60 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | Buy Now | 227.87% | RBC Capital | Luca Issi42% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 02/07/2024 | Buy Now | 136.07% | Morgan Stanley | Michael Ulz63% | $34 → $36 | Maintains | Equal-Weight | Get Alert |
| 02/07/2024 | Buy Now | 122.95% | Citigroup | Shawn Egan51% | $33 → $34 | Maintains | Neutral | Get Alert |
| 01/16/2024 | Buy Now | 227.87% | RBC Capital | Luca Issi42% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/02/2024 | Buy Now | 142.62% | B of A Securities | Jason Gerberry59% | $29 → $37 | Maintains | Buy | Get Alert |
| 12/04/2023 | Buy Now | 90.16% | B of A Securities | Jason Gerberry59% | → $29 | Initiates | → Buy | Get Alert |
| 11/30/2023 | Buy Now | 142.62% | Morgan Stanley | Michael Ulz63% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/30/2023 | Buy Now | 227.87% | RBC Capital | Luca Issi42% | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2023 | Buy Now | 116.39% | Citigroup | Shawn Egan51% | → $33 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 208.2% | Cantor Fitzgerald | Alethia Young76% | $79 → $47 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 293.44% | RBC Capital | Luca Issi42% | → $60 | Reiterates | Outperform → Outperform | Get Alert |
| 07/21/2023 | Buy Now | — | TD Cowen | Brendan Smith27% | — | Initiates | → Outperform | Get Alert |
| 07/20/2023 | Buy Now | 260.66% | B. Riley Securities | Mayank Mamtani71% | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 286.89% | Piper Sandler | Edward Tenthoff50% | $52 → $59 | Maintains | Overweight | Get Alert |
| 06/02/2023 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 162.3% | SVB Leerink | Mani Foroohar47% | → $40 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/03/2023 | Buy Now | 293.44% | RBC Capital | Luca Issi42% | → $60 | Reiterates | → Outperform | Get Alert |
| 05/03/2023 | Buy Now | 378.69% | Goldman Sachs | Madhu Kumar72% | $65 → $73 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 162.3% | Morgan Stanley | Michael Ulz63% | $37 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/26/2023 | Buy Now | 424.59% | SMBC Nikko | David Hoang42% | → $80 | Initiates | → Outperform | Get Alert |
| 04/12/2023 | Buy Now | 129.51% | SVB Securities | Mani Foroohar47% | $21 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/21/2023 | Buy Now | 77.05% | Bernstein | William Pickering38% | → $27 | Initiates | → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | → $90 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 293.44% | Chardan Capital | Keay Nakae55% | → $60 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 260.66% | B. Riley Securities | Mayank Mamtani71% | $59 → $55 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 404.92% | RBC Capital | Luca Issi42% | $83 → $77 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 280.33% | Baird | Joel Beatty67% | $60 → $58 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 240.98% | Piper Sandler | Edward Tenthoff50% | $55 → $52 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 490.16% | HC Wainwright & Co. | Patrick Trucchio46% | $110 → $90 | Maintains | Buy | Get Alert |
| 11/30/2022 | Buy Now | 286.89% | B. Riley Securities | Mayank Mamtani71% | $65 → $59 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 391.8% | Jefferies | Maury Raycroft32% | $92 → $75 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 142.62% | Morgan Stanley | Andrew Galler32% | $41 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 103.28% | SVB Leerink | Mani Foroohar47% | $33 → $31 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | 319.67% | Piper Sandler | Edward Tenthoff50% | $72 → $64 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 116.39% | SVB Leerink | Mani Foroohar47% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 168.85% | Morgan Stanley | Andrew Galler32% | → $41 | Initiates | → Equal-Weight | Get Alert |
| 08/08/2022 | Buy Now | 326.23% | Goldman Sachs | Madhu Kumar72% | $58 → $65 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 621.31% | HC Wainwright & Co. | Patrick Trucchio46% | $100 → $110 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 332.79% | Goldman Sachs | Madhu Kumar72% | $90 → $66 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Arrowhead Pharma (ARWR) stock?
The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by HC Wainwright & Co. on May 20, 2025. The analyst firm set a price target for $80.00 expecting ARWR to rise to within 12 months (a possible 424.59% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arrowhead Pharma (ARWR)?
The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by HC Wainwright & Co., and Arrowhead Pharma reiterated their buy rating.
When was the last upgrade for Arrowhead Pharma (ARWR)?
The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.
When was the last downgrade for Arrowhead Pharma (ARWR)?
The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Arrowhead Pharma (ARWR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating Arrowhead Pharma (ARWR) correct?
While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $80.00 to $80.00. The current price Arrowhead Pharma (ARWR) is trading at is $15.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
